IP Library Granted Patent US 10,167,478
Granted Patent B2
US 10,167,478 · App. 15/096,517 · Granted Jan 1, 2019

Replicative minicircle vectors with improved expression

Inventor: James A. Williams (Lincoln, NE)
Assignee: Nature Technology Corporation
C12N15/79C12N15/63C12N15/64C12N15/67C12N15/85C12P19/34C12P21/00A61K48/00C12N2800/107C12N2800/24C12N2820/55C12N2830/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,167,478
App. No.
15/096,517
Granted
Jan 1, 2019
Kind
B2
Abstract

The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules.

Claims (29)

1. A method of constructing a eukaryotic replicative minicircle expression vector and expressing a gene of interest therefrom comprising:

a) combining i) a eukaryotic region with 5′ and 3′ ends encoding a gene of interest and comprising an intron, the intron comprising a 5′ splice donor and a 3′ acceptor branch site, a bacterial replication origin selected from the group consisting of R6K replication origin, and ColE2-P9 replication origin, and an RNA selectable marker; with ii) a spacer region linking the 5′ and 3′ ends of the eukaryotic region, said spacer region being less than 500 basepairs in length, to create a eukaryotic replicative minicircle expression vector; and

b) introducing said replicative minicircle expression vector into a target eukaryotic cell or a eukaryotic organism comprising the target eukaryotic cell, under conditions wherein the target eukaryotic cell is transfected and said gene of interest is expressed.

2. The method of claim 1 , wherein said RNA selectable marker is an RNA-IN regulating RNA-OUT functional variant with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO:20, and SEQ ID NO:22.

3. The method of claim 1 , wherein said RNA selectable marker is selected from the group consisting of:

an RNA-OUT selectable marker that encodes an RNA-IN regulating RNA-OUT RNA with at least 95% sequence identity to SEQ ID NO: 21;

an RNAI selectable marker that encodes an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 33;

an IncB RNAI selectable marker encoding an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 35; and

an synthetic RNA selectable marker encoding an RNA selectable marker complement regulating RNA with at least 95% sequence identity to SEQ ID NO: 38.

4. The method of claim 1 , wherein said intron with a 5′ splice donor and a 3′ acceptor branch site is a functional variant with at least 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10.

5. The method of claim 1 , wherein said pUC replication origin and said RNA selectable marker positioned within said intron is a functional variant with at least 95% sequence identity to SEQ ID NO: 29.

6. A method of constructing a eukaryotic replicative minicircle expression vector comprising:

a) combining i) a eukaryotic region with 5′ and 3′ ends encoding a gene of interest and comprising an intron the intron comprising a 5′ splice donor and a 3′ acceptor branch site, a bacterial region comprising an R6K origin or a ColE2-P9 bacterial replication origin, and a RNA selectable marker with ii) a spacer region linking the 5′ and 3′ ends of the eukaryotic region sequences, said spacer region being less than 500 basepairs in length, to create a eukaryotic replicative minicircle expression vector;

b) transforming said replicative minicircle expression vector into cells of an RNA selectable marker regulated bacterial cell line;

c) isolating the resultant transformed bacterial cells by selection; and

d) propagating the resultant transformed bacterial cells in culture.

7. The method of claim 6 , wherein said RNA selectable marker is an RNA-IN regulating RNA-OUT functional variant with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO:20, and SEQ ID NO:22.

8. The method of claim 6 , wherein said RNA selectable marker is selected from the group consisting of:

an RNA-OUT selectable marker that encodes an RNA-IN regulating RNA-OUT RNA with at least 95% sequence identity to SEQ ID NO: 21;

an RNAI selectable marker that encodes an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 33;

an IncB RNAI selectable marker encoding an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 35; and

an synthetic RNA selectable marker encoding an RNA selectable marker complement regulating RNA with at least 95% sequence identity to SEQ ID NO: 38.

9. The method of claim 6 , wherein said intron with a 5′ splice donor and a 3′ acceptor branch site is a functional variant with at least 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10.

10. The method of claim 6 , wherein said pUC replication origin and said RNA selectable marker positioned within said intron is a functional variant with at least 95% sequence identity to SEQ ID NO: 29.

11. A eukaryotic replicative minicircle expression vector comprising i) a eukaryotic region sequence with 5′ and 3′ ends encoding a gene of interest and comprising an intron, the intron comprising a 5′ splice donor and a 3′ acceptor branch site, a bacterial replication origin selected from the group consisting of R6K replication origin, and ColE2-P9 replication origin, and an RNA selectable marker; and ii) a spacer region of less than 500 basepairs in length linking the 5′ and 3′ ends of the eukaryotic region sequences.

12. The vector of claim 11 , wherein said RNA selectable marker is an RNA-IN regulating RNA-OUT functional variant with at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO:20, and SEQ ID NO:22.

13. The vector of claim 11 , wherein said RNA selectable marker is selected from the group consisting of: an RNA-OUT selectable marker that encodes an RNA-IN regulating RNA-OUT RNA with at least 95% sequence identity to SEQ ID NO: 21; an RNAI selectable marker that encodes an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 33; an IncB RNAI selectable marker encoding an RNAII regulating RNAI RNA with at least 95% sequence identity to SEQ ID NO: 35; an synthetic RNA selectable marker encoding an RNA selectable marker complement regulating RNA with at least 95% sequence identity to SEQ ID NO: 38.

14. The vector of claim 11 , wherein said intron with a 5′ splice donor and a 3′ acceptor branch site is a functional variant with at least 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10.

15. The vector of claim 11 , wherein said pUC replication origin and said RNA selectable marker positioned within said intron is a functional variant with at least 95% sequence identity to SEQ ID NO: 29.

Assignments (2)
MERGER Recorded Feb 22, 2023
From: NATURE TECHNOLOGY CORPORATION
To: ALDEVRON, L.L.C.
Reel/Frame 062770/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2019
From: WILLIAMS, JAMES A.
To: NATURE TECHNOLOGY CORPORATION
Reel/Frame 049126/0262 →
Priority Claims (2)
WO PCT/US2013/000067 · Mar 14, 2013 · international
WO PCT/US2013/000068 · Mar 14, 2013 · international
Continuity (3)
Division 14432693
Provisional Application 61796765 · Nov 19, 2012
Related Publication 20160215296A1 · Jul 28, 2016
Cited By (2)
US 12,473,567 US 12,473,568